Fluoroquinolones compared to 1% azithromycin in DuraSite for bacterial conjunctivitis - PubMed (original) (raw)

Fluoroquinolones compared to 1% azithromycin in DuraSite for bacterial conjunctivitis

Steven J Lichtenstein et al. Clin Ophthalmol. 2008 Mar.

Free PMC article

No abstract available

PubMed Disclaimer

References

    1. Ambrose PG, Blast D, Doern CV, et al. Fluoroquinolone-resistant streptococcus pneumoniae, an emerging but unrecognized public health concern: is it time to resight the goal post? Clin Infect Dis. 2004;39:1554–6. -PubMed
    1. AzaSite. AzaSite Package Insert. Durham, NC: Inspire Pharmaceuticals, Inc [online]; 2007. [Accessed November 8th, 2007]. URL: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
    1. Friedlaender MH, Protzko E. Clinical development of 1% azithromycin in DuraSite®, a topical azalide anti-infective for ocular surface therapy. Clin Ophthalmol. 2007;1:3–10. -PMC -PubMed
    1. Goldstein MH, Kowalski RP, Gordan YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology. 1999;106:1313–18. -PubMed
    1. Granet DB, Lichtenstein SJ, Onofrey B, et al. An assessment of the tolerability of moxifloxacin 0.5% compared to azithromycin 1.0% in DuraSite®. Clin Ophthalmol. 2007;1:519–25. -PMC -PubMed

LinkOut - more resources